| Audience | Older adults who use cannabis, families and caregivers, clinicians who counsel older patients, and readers interested in cannabis-related driving safety. |
| Primary Topic | An active Colorado observational study examining cannabis, simulated driving, and cognitive performance in adults ages 65 and older. |
| Source | Read the full source |
Colorado Study Tests Cannabis Driving Effects in Adults 65 and Older
Colorado researchers are testing how older adults perform on a driving simulator before and after using their own cannabis. The study addresses an important evidence gap, but it is still collecting data and has not established a safe waiting period for driving.
| News report | Rocky Mountain PBS, August 12, 2026 |
| Research team | Colorado School of Public Health investigators Carolyn DiGuiseppi, PhD, MD, MPH, and Ashley Brooks-Russell, PhD, MPH |
| Population | Adults ages 65 to 89 who use cannabis and currently drive |
| Design | Observational, within-person comparison using self-provided cannabis |
| Procedures | Up to three visits, surveys, biological samples, cognitive testing, and simulated driving |
| Route studied | Participants smoke or vape cannabis they purchased themselves |
| Current stage | Roughly halfway through a 12-month data-collection period, according to Rocky Mountain PBS |
| Results | Not yet available |
| Expected reporting | Investigators hope to share results within about two years |
| What it cannot answer today | A safe post-use waiting interval for driving |
Rocky Mountain PBS reported that Colorado researchers are recruiting and testing adults 65 and older to examine how cannabis use affects simulated driving and cognitive performance. Participants complete testing when sober and after using cannabis they obtained themselves.
The Colorado School of Public Health study page independently confirms the investigators and procedures. The project includes surveys, urine and breath testing, blood draws, thinking and memory assessments, and a driving simulator.
This study does not provide a new rule for how many hours an older adult should wait before driving. It is still collecting data, and individual impairment can be influenced by dose, THC concentration, route, prior exposure, sleep, alcohol, other drugs, and prescription medications.
If cannabis causes sleepiness, slowed thinking, dizziness, altered perception, or poor coordination, do not drive. Families can help by planning transportation before use rather than trying to judge impairment afterward.
The report supports asking older patients about cannabis in the same medication-safety conversation as sedatives, sleep aids, opioids, antihistamines, and alcohol. The clinically useful question is not only whether a patient uses cannabis, but also product type, route, dose, frequency, timing, co-use, and whether driving follows use.
Counseling should remain individualized and conservative because this study has not reported outcomes and a simulator cannot capture every demand of real-world driving.
Older adults are increasingly represented among people who use cannabis, yet research samples often exclude them because of medical conditions or medications. That exclusion makes it harder to translate findings from younger adults into safe counseling for older patients.
A prior peer-reviewed cohort study of 31 regular cannabis users ages 65 to 79 found more lane weaving and lower speed 30 minutes after smoking, with subjective effects persisting longer. That small study offers context, but it does not predetermine the Colorado project’s findings or establish a universal waiting period.
The Colorado project studies smoked or vaped, self-selected products. Its eventual results may not generalize to edibles, beverages, tinctures, or standardized medicines, which can have different onset and duration profiles.
The study is observational. Product potency, dose, tolerance, medications, and health status may differ across participants. Simulator performance is informative but is not identical to collision risk on public roads.
Driving policy needs measures that relate to functional impairment, not assumptions based only on age or a positive cannabis test. The study may eventually help refine that discussion, but it is too early to claim that it validates any legal threshold or enforcement tool.
Public messaging should avoid both extremes: cannabis use should not be treated as proof of current impairment, and legal or medical access should not be treated as proof that driving after use is safe.
Cannabis-driving research has repeatedly struggled to translate product exposure or blood THC into a simple measure of functional impairment. Age adds another layer because metabolism, cognition, vision, mobility, and medication burden vary widely among older adults.
The useful public-health contribution of this project will depend on its completed sample, transparent methods, effect estimates, uncertainty, and peer-reviewed reporting. Until then, the study should be understood as evidence being gathered, not evidence already settled.
I am glad to see older adults included directly in this work. Patients in this age group are not simply older versions of younger study participants. Medication burden, balance, vision, sleep, and cognitive reserve can all shape the safety conversation.
The practical message today is not complicated: this study has not produced a safe waiting-time rule. Patients should plan not to drive after using cannabis when impairment is possible, and clinicians should ask about timing, route, dose, other substances, and the patient’s actual transportation plan.
How to Read News About a Cannabis Study That Is Still Underway
Research-in-progress stories can be valuable when they identify an important unanswered question. They become misleading when the question is written as though researchers have already found the answer.
This Colorado project deserves attention because it directly includes older adults and measures driving-related performance. Its conclusions must wait for completed data and peer review.
Four questions for careful readers
Are results available?
No. The team is still collecting data and expects reporting on a longer timeline.
What is actually being measured?
Simulated driving, thinking and memory performance, biological samples, and participant-reported information before and after self-provided inhaled cannabis.
Who is represented?
The study targets adults ages 65 to 89 who use cannabis and drive, subject to health and eligibility requirements.
What would make the findings useful?
Transparent reporting of the sample, products, timing, outcomes, uncertainty, medication context, and limits of simulator-to-road translation.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
Do Not Turn a Study Announcement Into a Waiting-Time Rule
The study has no results yet, and it examines inhaled products rather than every cannabis route.
Plan transportation before use and avoid driving whenever impairment is possible.
Ask About the Whole Exposure Context
Route, dose, THC concentration, frequency, timing, alcohol, and sedating medications all matter to counseling.
Document the patient’s driving demands and transportation plan, not just cannabis use status.
Methods Are Not Outcomes
Investigator interviews and recruitment pages can verify what a study intends to do, but not what it will find.
Wait for completed, peer-reviewed results before accepting claims about magnitude, duration, or subgroup differences.
Make Transportation the Easy Choice
Families can reduce risk by arranging rides before cannabis use rather than debating impairment afterward.
Concerns about confusion, falls, medication interactions, or unsafe driving deserve a calm clinical conversation.
Naturalistic Products Improve Relevance and Add Variability
Allowing participants to use their own products reflects real behavior more closely than a single standardized dose.
It also makes dose, potency, and product differences important analytical challenges.
Functional Evidence Matters More Than Assumptions
Policy should distinguish recent use, measurable impairment, and residual detectability.
This project may add evidence later, but it cannot validate a legal threshold before results exist.
Older Adults Belong in Safety Research
Excluding medically complex older adults can leave the population most in need of counseling without directly applicable evidence.
Future studies will still need to address routes beyond smoking and vaping and the effects of common medication combinations.
The Results and Their Limits Matter Next
Watch for final enrollment, product characteristics, timing of testing, effect estimates, subgroup analyses, and peer-reviewed publication.
The most important follow-up will be whether observed simulator changes translate into clinically useful counseling without false precision.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is the Colorado older-adult cannabis driving study?
It is an observational Colorado School of Public Health study measuring simulated driving and cognitive performance in adults ages 65 to 89 before and after they use their own inhaled cannabis.
Has the study reported results?
No. Rocky Mountain PBS reported that the team is roughly halfway through a 12-month data-collection period and hopes to share results within about two years.
Does the study establish how long to wait before driving?
No. It has not reported results and does not provide a validated waiting-time rule for any individual or product.
What kind of cannabis do participants use?
Participants smoke or vape cannabis they obtained themselves, making the exposure naturalistic but variable in product, potency, and dose.
Why focus on adults 65 and older?
Older adults are often excluded from cannabis-driving experiments even though age-related changes, health conditions, and medications may affect impairment and counseling needs.
Is a driving simulator the same as real-road driving?
No. A simulator can measure standardized driving behaviors without putting the public at risk, but it cannot reproduce every condition or consequence of driving on public roads.
Can a blood THC level prove driving impairment?
A blood THC result does not by itself provide a simple, universally reliable measure of functional impairment. Timing, use pattern, product, and individual factors complicate interpretation.
What should older patients discuss with clinicians?
Discuss route, dose, THC concentration, timing, frequency, other medications or substances, dizziness or sedation, and plans for transportation after use.
What should patients do until results are available?
Avoid driving whenever cannabis-related impairment is possible, plan transportation before use, and do not rely on an unvalidated waiting interval.
What evidence should careful readers look for next?
Look for completed enrollment, transparent product and timing data, effect estimates with uncertainty, medication context, limitations, and peer-reviewed publication.
